Arcus Biosciences (RCUS) Non-Current Debt (2024 - 2026)

Arcus Biosciences' Non-Current Debt history runs 3 years deep, the most recent figure standing at $100.0 million for Q1 2026.

• In Q1 2026, Non-Current Debt rose 108.33% year-over-year to $100.0 million; the TTM figure through Mar 2026 stood at $100.0 million (up 108.33% YoY), while the FY2025 annual figure was $99.0 million, up 106.25% from the prior year.
• Non-Current Debt for Q1 2026 stood at $100.0 million, up from $99.0 million in the prior quarter.
• The five-year high for Non-Current Debt was $100.0 million in Q1 2026, with the low at $47.0 million in Q3 2024.
• The 3-year median for Non-Current Debt is $97.0 million (2025), against an average of $76.7 million.
• Peak annual rise in Non-Current Debt reached 108.51% in 2025, while the deepest fall reached 106.25% in 2025.
• Arcus Biosciences' Non-Current Debt stood at $48.0 million in 2024, then surged by 106.25% to $99.0 million in 2025, then grew by 1.01% to $100.0 million in 2026.
• Business Quant data shows RCUS's Non-Current Debt at $100.0 million in Q1 2026, $99.0 million in Q4 2025, and $98.0 million in Q3 2025.